{
    "nctId": "NCT00444535",
    "briefTitle": "Lapatinib and Bevacizumab for Metastatic Breast Cancer",
    "officialTitle": "A Phase II, Open-Label Study of the Clinical Activity, Safety, and Tolerability of Lapatinib in Combination With Bevacizumab in Subjects With Advanced or Metastatic ErbB2-Overexpressing Breast Cancer",
    "overallStatus": "COMPLETED",
    "conditions": "Neoplasms, Breast",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE2",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 52,
    "primaryOutcomeMeasure": "Investigator-evaluated Crude Progression-free Survival Rate After 12 Weeks of Study Treatment",
    "eligibilityCriteria": "Inclusion criteria:\n\n* Females that are at least 18 years of age.\n* Women of childbearing potential must have a negative serum pregnancy test at screening.\n* Documented evidence of HER2-overexpressing unresectable or metastatic breast cancer. Disease may/may not have been treated in metastatic setting.\n* Subjects are permitted (but not required) to have previously-treated brain metastases that are stable and asymptomatic.\n* Adequate hepatic, renal and cardiac function\n* ECOG score 0-1 and a life expectancy of at least 12 weeks.\n* Able to swallow oral medication\n* Signed informed consent\n\nExclusion criteria:\n\n* Pregnancy\n* Unstable or symptomatic CNS metastases\n* Major surgery within 28 days of enrollment (minor surgery within 7 days).\n* Prior anti-cancer treatment within 14 days of enrollment, or unresolved treatment-related toxicities.\n* A serious non-healing wound, ulcer, or bone fracture at baseline.\n* Class II, III or IV heart failure as defined by the NYHA functional classification system\n* History of significant vascular disease, arterial thrombosis, unstable INR, hypertensive crisis, or uncontrolled hypertension.\n* History of myocardial infarction, stenting procedure, or angioplasty within 6 months of enrollment.\n* History of abdominal fistulae, gastrointestinal perforation, or intra-abdominal abscess within 6 months of enrollment.\n* History of malabsorption syndrome, ulcerative colitis, or bowel obstruction.\n* Proteinuria\n* Requires concurrent anti-cancer treatment or investigational treatment.\n* Known hypersensitivity to either study medication\n* Received investigational treatment within 28 days or 5 half-lives, whichever is longer\n* Concurrent disease or circumstances that would lead the investigator would consider the subject an inappropriate candidate for the study\n* Requires medication that has been excluded during study participation",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}